Search results for drug and therapeutics bulletin:
Little or no evidence that herbal remedies relieve menopausal symptoms
Jan 14, 2009 |
5 / 5 (1) |
0
There is no strong evidence either way for several herbal remedies commonly taken to relieve troublesome menopausal symptoms, concludes the January issue of the Drug and Therapeutics Bulletin (DTB). And for some, there i ...
Moves to make more prescription drugs available over the counter won't help patients or doctors
Medicine & Health / Medications
Jan 14, 2009 |
not rated yet |
0
Government plans to make certain prescription-only drugs for common problems available over the counter have overwhelmingly been given the thumbs down by healthcare professionals, reveals a survey of readers of the influential ...
No 'convincing evidence' that glitazones work better than older diabetes drugs
Medicine & Health / Medications
Apr 10, 2008 |
3.3 / 5 (3) |
0
There is no convincing evidence that the newer class of diabetes drugs, known as glitazones, offer real advantages over other diabetes drugs, when used on their own, concludes the Drug and Therapeutics Bulletin (DTB).
Appealing the death sentence for brain cells
May 29, 2008 |
5 / 5 (5) |
0
A new drug candidate discovered by Tel Aviv University researcher Prof. Illana Gozes may lead to an effective treatment against the debilitative Alzheimer's disease. This compound could also treat a number of diseases where ...
When It Comes to Drug Delivery, Size Matters
Nanotechnology / Bio & Medicine
Nov 20, 2009 |
5 / 5 (2) |
0
(PhysOrg.com) -- One of the great promises of nanotechnologies lies in its ability to create drug-containing nanoparticles decorated with targeting molecules that recognize and bind to cancer cells, providing drug delivery ...
FDA issues alert about HIV drug Prezista
Medicine & Health / HIV & AIDS
Mar 24, 2008 |
5 / 5 (1) |
0
The U.S. Food and Drug Administration has issued an alert concerning reports of liver injury in patients taking Prezista.
Alzheimer's disease: A new small molecule approach to treatment
Apr 13, 2009 |
4.7 / 5 (3) |
0
New therapeutic approaches in Alzheimer's disease are urgently needed. Work led by Professor Mark Pepys FRS over more than 20 years has identified a protein known as serum amyloid P component (SAP) as a possible therapeutic ...
Business of drug development on verge of great change
Apr 01, 2008 |
5 / 5 (1) |
0
Significant changes to drug discovery and the pharmaceutical industry currently underway will increase in the next five to 10 years, according to a top researcher at the National Institutes of Health (NIH) who is helping ...
Enzyme inhibitor takes an unexpected approach toward blocking cancer-promoting protein
Sep 08, 2009 |
not rated yet |
0
Scientists at Fox Chase Cancer Center have discovered a unique method of attack that may be used to inhibit signaling enzymes called kinases, which often have a role in sustaining drug-resistant cancerous cells. They have ...
Thumbs down for new testosterone patch to boost women's sex drive
Mar 03, 2009 |
4 / 5 (1) |
1
A new testosterone patch, designed to pep up a woman's flagging sex drive after womb and ovary removal, may not work, and its long term safety is not proven, says Drug and Therapeutics Bulletin (DTB).
Microfluidic Device Mimics Tumor Microenvironment, Helps Drug Discovery Efforts
Feb 23, 2009 |
not rated yet |
1
One of the challenges that cancer researchers face in designing new antitumor agents is that of predicting how drug molecules will behave in the complex microenvironment that surrounds a tumor. In particular, tumors create ...
Dismissed leukemia drug helps CLL patients, studies show
Medicine & Health / Medications
Dec 08, 2008 |
4.9 / 5 (8) |
0
Researchers at Ohio State devised a new dosing schedule for the drug to increase its anti-tumor activity.
Improved rodent trials can speed cancer drug development
Oct 28, 2008 |
not rated yet |
0
Better design of rodent trials could reduce the cost and time required for cancer drug development, according to a commentary in the October 28 online issue of the Journal of the National Cancer Institute.
Is inhaled insulin delivery still a possibility? Why has it been a commercial failure?
Sep 23, 2009 |
not rated yet |
0
The commercial failure of Exubera (Pfizer, New York, NY), the first inhaled insulin product to come to market, led other companies such as Eli Lilly-Alkermes to halt studies of similar drug delivery in development intended ...
New computational technique can predict drug side effects
Biology /
Dec 11, 2007 |
4.3 / 5 (3) |
0
Early identification of adverse effects of drugs before they are tested in humans is crucial in developing new therapeutics, as unexpected effects account for a third of all drug failures during the development process.
